DR. GREGORY MICHAEL BELL, MD
Osteopathic Medicine at Trinidad Dr, Tiburon, CA
License number
California G63151
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
157 Trinidad Dr, Tiburon, CA 94920
Phone
(415) 435-6210
Organization information
See more information about GREGORY MICHAEL BELL at bizstanding.comOfc of Gregory Michael Bell MD
157 Trinidad Dr, Tiburon, CA 94920
Status:
Inactive
Industry:
Trust Management
Professional information
Therapeutic Agents For Regulating Serum Phosphorus
US Patent:
2013015, Jun 13, 2013
Filed:
Jun 8, 2012
Appl. No.:
13/492778
Inventors:
Felix Karim - Walnut Creek CA, US
Gregory Bell - Tiburon CA, US
Gregory Bell - Tiburon CA, US
Assignee:
KAI Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07K 7/06, A61K 38/08, A61K 45/06
US Classification:
514 135, 514654
Abstract:
Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X—X—X—X—X—X—X, wherein the Xsubunit comprises a thiol-containing moiety and the distribution of charge on the X-Xsubunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers serum phosphorus levels, relative to pre-dosing levels, and achieves a sustained reduced level for a period of time after administration.
Methods For Treating Chronic Obstructive Pulmonary Disease (Copd)
US Patent:
2003023, Dec 18, 2003
Filed:
Mar 18, 2003
Appl. No.:
10/392635
Inventors:
Xiao-dong Yang - Palo Alto CA, US
Gregory Bell - Tiburon CA, US
Ronald Gladue - Stonington CT, US
Elizabeth Kudlacz - Groton CT, US
Henry Showell - Westbrook CT, US
Gregory Bell - Tiburon CA, US
Ronald Gladue - Stonington CT, US
Elizabeth Kudlacz - Groton CT, US
Henry Showell - Westbrook CT, US
International Classification:
A61K039/395
US Classification:
424/141100, 424/145100
Abstract:
The present disclosure relates to methods of treating Chronic Obstructive Pulmonary Disease (COPD) and its various indications, particularly including chronic bronchitis, emphysema, and irreversible asthma. Treatment regimens generally include the administration of anti-interleukin-8 antibodies to the patient to reduce the severity of an inflammatory response by the patient's immune system.
Antibodies Against Parathyroid Hormone
US Patent:
2006006, Mar 23, 2006
Filed:
Sep 30, 2004
Appl. No.:
10/956008
Inventors:
Lorin Roskos - Pleasanton CA, US
Ian Foltz - Burnaby, CA
Chadwick King - Vancouver, CA
Gregory Bell - Tiburon CA, US
Ian Foltz - Burnaby, CA
Chadwick King - Vancouver, CA
Gregory Bell - Tiburon CA, US
International Classification:
A61K 39/395
US Classification:
424141100, 424145100
Abstract:
Embodiments of the invention described herein relate to antibodies directed to the antigen parathyroid hormone (PTH) and uses of such antibodies. In particular, in some embodiments, there are provided fully human monoclonal antibodies directed to the antigen PTH. In further embodiments, nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided.
Polycationic Calcium Modulator Peptides For The Treatment Of Hyperparathyroidism And Hypercalcemic Disorders
US Patent:
2009002, Jan 22, 2009
Filed:
Nov 16, 2007
Appl. No.:
11/941857
Inventors:
Gregory Bell - Tiburon CA, US
Sarah Walter - Redwood City CA, US
Felix Karim - Walnut Creek CA, US
Sarah Walter - Redwood City CA, US
Felix Karim - Walnut Creek CA, US
International Classification:
A61K 38/00, C07K 14/00, C07K 7/00, A61P 19/00
US Classification:
514 12, 514 18, 514 17, 514 16, 514 15, 514 14, 514 13, 530330, 530329, 530328, 530327, 530326, 530325, 530324
Abstract:
The present invention provides methods and kits for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders. In particular, methods for lowering serum PTH and serum calcium using polycationic calcium modulator peptides are provided. The calcium modulator peptides can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.